SCHEMBL13879591

SCHEMBL13879591

COc1ccccc1N1C(=O)NC(C)(Cc2ccccc2)C1=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.47
ITGAL P20701 1/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD11B1 P28845 2/20 0.42
ALOX15 P16050 1/20 0.42
ELANE P08246 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR7 P34969 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879517 0.81 ITGAL (0.51) MGLLITGALALDH1A1SMN1; SMN2HSD11B1
SCHEMBL13879409 0.79 ITGAL (0.49) MGLLITGALALDH1A1SMN1; SMN2HSD11B1
SCHEMBL11569756 0.79 ELANE (0.61) ITGALALDH1A1ELANELMNA
SCHEMBL13879421 0.77 ITGAL (0.50) MGLLITGALALDH1A1ELANEMAPT
SCHEMBL13879533 0.73 ITGAL (0.76) ITGALELANE
SCHEMBL13879502 0.73 ITGAL (0.61) ITGALALDH1A1SMN1; SMN2ELANELMNA
SCHEMBL1514022 0.73 ITGAL (0.48) ITGALALDH1A1SMN1; SMN2ELANEMAPT
SCHEMBL12542988 0.73 ITGAL (0.48) ITGALALDH1A1SMN1; SMN2ELANEMAPT
SCHEMBL1514026 0.73 ITGAL (0.48) ITGALALDH1A1SMN1; SMN2ELANEMAPT
SCHEMBL13879461 0.72 MGLL (0.51) MGLLALDH1A1ALOX15LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 MGLL 2140/4885ITGAL 4495/4885ALDH1A1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.